Multi-modal assessment of an anti-HER2 (trastuzumab) antibody-drug conjugate screening assay for breast cancer models. Zaitouna A et al. AACR2025

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment by combining the targeting ability of monoclonal antibodies with cytotoxic drugs. Various breast cancer cell lines with different HER-2 levels were screened to reveal that Trastuzumab ADCs show higher binding efficiency (EC50) and cytotoxicity (IC50) in HER-2 positive cells. Additionally, bystander assays suggest potential efficacy in heterogeneous HER-2 expressing tumors. These findings underscore the potential of Trastuzumab ADCs to improve breast cancer treatment by targeting both HER-2 positive tumor cells and HER-2 negative cells in the tumor microenvironment.